Stem Cell Research & Therapy (Apr 2021)

Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells

  • Belén Álvarez-Palomo,
  • Iris García-Martinez,
  • Jorge Gayoso,
  • Angel Raya,
  • Anna Veiga,
  • María Luisa Abad,
  • Adolfo Eiras,
  • María Guzmán-Fulgencio,
  • Mar Luis-Hidalgo,
  • Cristina Eguizabal,
  • Silvia Santos,
  • Antonio Balas,
  • Raquel Alenda,
  • Francisco Sanchez-Gordo,
  • Laura Ponce Verdugo,
  • Juliana Villa,
  • Enric Carreras,
  • Francisco Vidal,
  • Alejandro Madrigal,
  • María José Herrero,
  • Francesc Rudilla,
  • Sergi Querol

DOI
https://doi.org/10.1186/s13287-021-02301-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background iPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population. Methods To create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B, and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch. Results We have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population. Conclusion We confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will cover a significant percentage of the Spanish and international population for future advanced therapy replacement strategies.

Keywords